Ruoshuang J. Han
301 Yanchang Road
Shanghai, 200072, China
Shanghai, 200072, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 04, 2025
A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: May 19, 2025
Corrigendum to "Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer" [Eur J Cancer 189 (2023) 112919].
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 21, 2025
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Journal: BMC medicine
Published: September 20, 2024
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer.
Journal: Lung Cancer (Auckland, N.Z.)
Published: August 31, 2023
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Journal: BMC medicine
Published: July 08, 2023
Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 31, 2022
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection.
Journal: Translational lung cancer research
Published: July 15, 2021
Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance.
Journal: Translational lung cancer research
Published: April 23, 2021
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC.
Journal: Frontiers in oncology
Published: December 17, 2020
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Journal: Translational lung cancer research
Published: September 21, 2020
Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study.
Journal: Therapeutic advances in medical oncology
Published: September 14, 2020
Last Updated: 09/26/2026